Evolution of Liquid Biopsies for Detecting Pancreatic Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Oct 16

PMID 39409954

Authors

Ryan Munnings

Peter Gibbs

Belinda Lee

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterised by late diagnosis and poor prognosis. Despite advancements, current diagnostic and prognostic strategies remain limited. Liquid biopsy techniques, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), circulating tumour exosomes, and proteomics, offer potential solutions to improve PDAC diagnosis, prognostication, and management. A systematic search of Ovid MEDLINE identified studies published between 2019 and 2024, focusing on liquid biopsy biomarkers for PDAC. A total of 49 articles were included. ctDNA research shows some promise in diagnosing and prognosticating PDAC, especially through detecting mutant in minimal residual disease assays. CTC analyses had low sensitivity for early-stage PDAC and inconsistent prognostic results across subpopulations. Exosomal studies revealed diverse biomarkers with some diagnostic and prognostic potential. Proteomics, although relatively novel, has demonstrated superior accuracy in PDAC diagnosis, including early detection, and notable prognostic capacity. Proteomics combined with CA19-9 analysis has shown the most promising results to date. An update on multi-cancer early detection testing, given its significance for population screening, is also briefly discussed. Liquid biopsy techniques offer promising avenues for improving PDAC diagnosis, prognostication, and management. In particular, proteomics shows considerable potential, yet further research is needed to validate existing findings and comprehensively explore the proteome using an unbiased approach.

References

Sahni S, Krisp C, Molloy M, Nahm C, Maloney S, Gillson J . PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Biochim Biophys Acta Gen Subj. 2020; 1864(11):129682. DOI: 10.1016/j.bbagen.2020.129682. View

Semaan A, Bernard V, Kim D, Lee J, Huang J, Kamyabi N . Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. Br J Cancer. 2021; 124(12):1970-1977. PMC: 8185080. DOI: 10.1038/s41416-021-01350-9. View

Wei Q, Wei L, Zhang J, Li Z, Feng H, Ren L . EphA2‑enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer. Mol Med Rep. 2020; 22(4):2941-2947. PMC: 7466360. DOI: 10.3892/mmr.2020.11384. View

Stoecklein N, Fluegen G, Guglielmi R, Neves R, Hackert T, Birgin E . Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis. Mol Cancer. 2023; 22(1):181. PMC: 10641981. DOI: 10.1186/s12943-023-01880-1. View

Vicentini C, Calore F, Nigita G, Fadda P, Simbolo M, Sperandio N . Exosomal miRNA signatures of pancreatic lesions. BMC Gastroenterol. 2020; 20(1):137. PMC: 7204029. DOI: 10.1186/s12876-020-01287-y. View

Yu J, Ploner A, Kordes M, Lohr M, Nilsson M, de Maturana M . Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Int J Cancer. 2021; 148(8):2048-2058. DOI: 10.1002/ijc.33464. View

Stefanovic S, Deutsch T, Wirtz R, Hartkopf A, Sinn P, Schuetz F . Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. Cancers (Basel). 2019; 11(3). PMC: 6468370. DOI: 10.3390/cancers11030342. View

Shinjo K, Hara K, Nagae G, Umeda T, Katsushima K, Suzuki M . A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer. PLoS One. 2020; 15(6):e0233782. PMC: 7286528. DOI: 10.1371/journal.pone.0233782. View

Klein E, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D . Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32(9):1167-1177. DOI: 10.1016/j.annonc.2021.05.806. View

10.

Nadauld L, McDonnell 3rd C, Beer T, Liu M, Klein E, Hudnut A . The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. Cancers (Basel). 2021; 13(14). PMC: 8304888. DOI: 10.3390/cancers13143501. View

11.

Giampieri R, Piva F, Occhipinti G, Bittoni A, Righetti A, Pagliaretta S . Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS One. 2019; 14(5):e0215990. PMC: 6497273. DOI: 10.1371/journal.pone.0215990. View

12.

Sharma A, Kandlakunta H, Nagpal S, Feng Z, Hoos W, Petersen G . Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology. 2018; 155(3):730-739.e3. PMC: 6120785. DOI: 10.1053/j.gastro.2018.05.023. View

13.

Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D . Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers (Basel). 2021; 13(5). PMC: 7956845. DOI: 10.3390/cancers13050994. View

14.

Aiello N, Kang Y . Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019; 216(5):1016-1026. PMC: 6504222. DOI: 10.1084/jem.20181827. View

15.

Miller B, Petrykowska H, Elnitski L . Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients. Sci Rep. 2021; 11(1):221. PMC: 7794477. DOI: 10.1038/s41598-020-80345-7. View

16.

Nakaoka K, Ohno E, Kawabe N, Kuzuya T, Funasaka K, Nakagawa Y . Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma. Diagnostics (Basel). 2023; 13(2). PMC: 9857526. DOI: 10.3390/diagnostics13020215. View

17.

Terasawa H, Kinugasa H, Ako S, Hirai M, Matsushita H, Uchida D . Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2019; 20(10):1348-1353. PMC: 6783121. DOI: 10.1080/15384047.2019.1638685. View

18.

Rittmann M, Hussung S, Braun L, Klar R, Biesel E, Fichtner-Feigl S . Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. Sci Rep. 2021; 11(1):7499. PMC: 8021576. DOI: 10.1038/s41598-021-86779-x. View

19.

Tempero M, Malafa M, Al-Hawary M, Asbun H, Bain A, Behrman S . Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(8):1028-1061. DOI: 10.6004/jnccn.2017.0131. View

20.

Guo S, Shi X, Shen J, Gao S, Wang H, Shen S . Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Br J Cancer. 2020; 122(6):857-867. PMC: 7078253. DOI: 10.1038/s41416-019-0704-2. View